New peptide analgesic, μ1-opioid receptor agonist tafalgin, in multimodal pain management. First results of using in a multidisciplinary hospital-Reference-Cited by-同舟云学术

New peptide analgesic, μ1-opioid receptor agonist tafalgin, in multimodal pain management. First results of using in a multidisciplinary hospital

Published:2024-03-25 Issue:1 Volume:4 Page:78-84
ISSN:2782-6171
Container-title:MD-Onco
language:
Short-container-title:jour

Author:

Gruzdev V. E.¹^ORCID,Anisimov M. A.¹^ORCID,Ryabukhina Yu. E.¹^ORCID,Oskolkov A. V.¹^ORCID,Zeynalova P. A.²^ORCID

Affiliation:

1. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

2. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Abstract

Therapy of chronic pain syndrome and adequate perioperative pain management during treatment of malignant neoplasms are important problems at the current stage of clinical medicine development. Currently, multimodal pain management is effectively applied through drugs of various pharmacological groups prescribed depending on pain intensity in accordance with a digital rating scale. Associated adverse events as well as impossibility of using peroral or transdermal forms in some cases, limit the use of opioid analgesics. High bioavailability and fast absorption of μ1-opioid receptor agonist tafalgin shown during preclinical studies, relatively favorable safety profile allowed to use this drug in oncological clinic.An experience of using tafalgin in treatment of pain syndrome in patients with malignant tumors at the “Lapino” clinical hospital since 2022 is presented. The effectiveness of the drug is evaluated, and its niche in multimodal pain management is determined.

Publisher

Publishing House ABV Press

Reference17 articles.

1. Gruzdev V.E., Anisimov M.A. Multimodal continuous approach to pain management in oncological patients (clinic’s first experience). MD-Onco 2022;2(1):33–8. (In Russ.). DOI: 10.17650/2782-3202-2022-2-1-33-38

2. Kosorukov V.S., Abuzarova G.R., Zakharochkina E.R. et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholi golovy i shei = Head and Neck Tumors 2022;12(2): 89–107. (In Russ.). DOI: 10.17650/2222-1468-2022-12-2-89-107

3. Abuzarova G.R., Kosorukov V.S., Gamzeleva O.Yu. et al. The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2022;11(5):38–48. (In Russ.). DOI: 10.17116/onkolog20221105138

4. Karelov A.E., Kosorukov V.S., Kraevskaya Yu.N. et al. Effectiveness of the new peptide analgesic Tafalgin in the treatment of postoperative pain. Anesteziologiya i reanimatologiya = Russian Journal of Anesthesiology and Reanimatology 2023;(6):75–83. (In Russ.). DOI: 10.17116/anaesthesiology202306175

5. Abuzarova G.R., Sarmanaeva R.R., Alekseev G.S. et al. Orofacial pain in oncology: use of a new analgesic peptide tafalgin. Opukholi golovy i shei = Head and Neck Tumors 2023;13(3):43–50. (In Russ.). DOI: 10.17650/2222-1468-2023-13-3-43-50

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New μ<sub>1</sub>-opioid receptor agonist for emergency pain relief in outpatient clinic: open observational nonrandomized uncontrolled study;Regional Anesthesia and Acute Pain Management;2024-08-01